ERP27
gene geneOn this page
Also known as FLJ32115PDIA8
Summary
ERP27 (endoplasmic reticulum protein 27, HGNC:26495) is a protein-coding gene on chromosome 12p12.3, encoding Endoplasmic reticulum resident protein 27 (Q96DN0). Specifically binds unfolded proteins and may recruit protein disulfide isomerase PDIA3 to unfolded substrates.
This gene encodes a noncatalytic member of the protein disulfide isomerase (PDI) family of endoplasmic reticulum (ER) proteins. The canonical protein has an N-terminal signal sequence, two thioredoxin (TRX)-like domains and a C-terminal ER-retention sequence. Alternative splicing results in multiple transcript variants encoding distinct isoforms; some of which lack domains present in the canonical protein.
Source: NCBI Gene 121506 — RefSeq curated summary.
At a glance
- GWAS associations: 5
- Clinical variants (ClinVar): 49 total
- MANE Select transcript:
NM_152321
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26495 |
| Approved symbol | ERP27 |
| Name | endoplasmic reticulum protein 27 |
| Location | 12p12.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ32115, PDIA8 |
| Ensembl gene | ENSG00000139055 |
| Ensembl biotype | protein_coding |
| OMIM | 610642 |
| Entrez | 121506 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 2 protein_coding, 1 protein_coding_CDS_not_defined
ENST00000266397, ENST00000540097, ENST00000544881
RefSeq mRNA: 2 — MANE Select: NM_152321
NM_001300784, NM_152321
CCDS: CCDS73450, CCDS8670
Canonical transcript exons
ENST00000266397 — 7 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000936299 | 14938415 | 14938537 |
| ENSE00000936300 | 14937952 | 14938052 |
| ENSE00000936301 | 14934856 | 14934993 |
| ENSE00000936302 | 14920932 | 14921048 |
| ENSE00000936309 | 14917178 | 14917303 |
| ENSE00000936310 | 14915489 | 14915686 |
| ENSE00001100133 | 14914039 | 14914782 |
Expression profiles
Bgee: expression breadth ubiquitous, 180 present calls, max score 99.40.
FANTOM5 (CAGE): breadth broad, TPM avg 1.9011 / max 1394.0271, expressed in 251 samples.
FANTOM5 promoters (10 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 129890 | 1.1204 | 41 |
| 129880 | 0.5626 | 193 |
| 129876 | 0.0620 | 24 |
| 129879 | 0.0437 | 16 |
| 129872 | 0.0356 | 8 |
| 129878 | 0.0284 | 9 |
| 129873 | 0.0201 | 8 |
| 129877 | 0.0120 | 5 |
| 129874 | 0.0116 | 6 |
| 129875 | 0.0047 | 1 |
Top tissues by expression
247 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| body of pancreas | UBERON:0001150 | 99.40 | gold quality |
| kidney epithelium | UBERON:0004819 | 97.23 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 95.11 | gold quality |
| right uterine tube | UBERON:0001302 | 93.48 | gold quality |
| pancreas | UBERON:0001264 | 93.17 | gold quality |
| oviduct epithelium | UBERON:0004804 | 92.55 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 89.83 | gold quality |
| metanephros cortex | UBERON:0010533 | 88.38 | gold quality |
| fallopian tube | UBERON:0003889 | 88.11 | gold quality |
| kidney | UBERON:0002113 | 87.11 | gold quality |
| metanephros | UBERON:0000081 | 84.78 | gold quality |
| tibialis anterior | UBERON:0001385 | 84.14 | gold quality |
| cortex of kidney | UBERON:0001225 | 83.70 | gold quality |
| islet of Langerhans | UBERON:0000006 | 81.88 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 81.54 | gold quality |
| ileal mucosa | UBERON:0000331 | 80.86 | gold quality |
| urinary bladder | UBERON:0001255 | 80.29 | gold quality |
| granulocyte | CL:0000094 | 79.86 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 78.08 | gold quality |
| blood | UBERON:0000178 | 77.89 | gold quality |
| renal medulla | UBERON:0000362 | 77.05 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 76.94 | gold quality |
| leukocyte | CL:0000738 | 76.79 | gold quality |
| right lung | UBERON:0002167 | 76.74 | gold quality |
| monocyte | CL:0000576 | 76.69 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 76.34 | gold quality |
| thyroid gland | UBERON:0002046 | 76.19 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 75.24 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 74.84 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 74.00 | gold quality |
Single-cell (SCXA)
Detected in 5 experiment(s), a significant marker in 5.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-81547 | yes | 1866.04 |
| E-GEOD-114530 | yes | 405.37 |
| E-MTAB-5061 | yes | 18.47 |
| E-MTAB-9388 | yes | 7.40 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
34 targeting ERP27, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6867-5P | 100.00 | 82.21 | 3464 |
| HSA-MIR-1252-5P | 100.00 | 69.80 | 2774 |
| HSA-MIR-216A-3P | 99.95 | 71.19 | 2505 |
| HSA-MIR-128-3P | 99.95 | 71.17 | 2484 |
| HSA-MIR-218-5P | 99.93 | 72.22 | 2103 |
| HSA-MIR-1321 | 99.84 | 65.30 | 1811 |
| HSA-MIR-4739 | 99.84 | 65.25 | 1832 |
| HSA-MIR-4756-5P | 99.84 | 64.98 | 1809 |
| HSA-MIR-130B-5P | 99.83 | 68.50 | 1888 |
| HSA-MIR-3128 | 99.50 | 67.85 | 1258 |
| HSA-MIR-657 | 99.48 | 66.02 | 848 |
| HSA-MIR-4797-5P | 99.39 | 68.01 | 1354 |
| HSA-MIR-593-3P | 99.22 | 67.28 | 1327 |
| HSA-MIR-4279 | 99.19 | 66.70 | 2437 |
| HSA-MIR-6071 | 99.16 | 67.77 | 1780 |
| HSA-MIR-143-5P | 98.98 | 68.87 | 946 |
| HSA-MIR-6760-5P | 98.87 | 66.73 | 1515 |
| HSA-MIR-5197-3P | 98.71 | 67.05 | 1905 |
| HSA-MIR-3928-5P | 98.50 | 67.48 | 980 |
| HSA-MIR-6806-3P | 98.50 | 67.31 | 980 |
| HSA-MIR-211-3P | 98.14 | 66.77 | 1052 |
| HSA-MIR-3921 | 97.81 | 67.45 | 1431 |
| HSA-MIR-127-5P | 97.78 | 67.64 | 869 |
| HSA-MIR-890 | 97.47 | 68.67 | 982 |
| HSA-MIR-3187-3P | 97.38 | 65.80 | 904 |
| HSA-MIR-4653-5P | 97.22 | 67.72 | 1429 |
| HSA-MIR-3201 | 97.16 | 65.42 | 1044 |
| HSA-MIR-5702 | 96.68 | 68.21 | 958 |
| HSA-MIR-12128 | 96.67 | 66.98 | 1471 |
| HSA-MIR-6866-5P | 96.64 | 68.06 | 624 |
Literature-anchored findings (GeneRIF, showing 3)
- ERp27 is bound by ERp57 both in vitro and in vivo by a similar mechanism by which ERp57 binds calreticulin (PMID:16940051)
- ERp27 is able to distinguish between folded and unfolded substrates, only interacting with the latter and presenting them to for catalysis. (PMID:23192347)
- High-resolution NMR studies of structure and dynamics of human ERp27 indicate extensive interdomain flexibility (PMID:23234573)
Cross-species orthologs
10 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Erp27 | ENSMUSG00000030219 |
| rattus_norvegicus | Erp27 | ENSRNOG00000005787 |
| drosophila_melanogaster | ERp60 | FBGN0033663 |
| drosophila_melanogaster | Tmx3 | FBGN0036579 |
| drosophila_melanogaster | Pdi | FBGN0286818 |
| caenorhabditis_elegans | WBGENE00003962 | |
| caenorhabditis_elegans | WBGENE00003963 | |
| caenorhabditis_elegans | pdi-3 | WBGENE00003964 |
| caenorhabditis_elegans | M04D5.1 | WBGENE00014807 |
| caenorhabditis_elegans | ZK973.11 | WBGENE00022836 |
Paralogs (13): ERP44 (ENSG00000023318), PDIA5 (ENSG00000065485), TMX4 (ENSG00000125827), TMX1 (ENSG00000139921), PDIA6 (ENSG00000143870), TXNDC11 (ENSG00000153066), PDIA4 (ENSG00000155660), TMX3 (ENSG00000166479), PDIA3 (ENSG00000167004), PDILT (ENSG00000169340), PDIA2 (ENSG00000185615), P4HB (ENSG00000185624), TXNDC5 (ENSG00000239264)
Protein
Protein identifiers
Endoplasmic reticulum resident protein 27 — Q96DN0 (reviewed: Q96DN0)
Alternative names: Inactive protein disulfide-isomerase 27
All UniProt accessions (2): Q96DN0, F5GYS6
UniProt curated annotations — full annotation on UniProt →
Function. Specifically binds unfolded proteins and may recruit protein disulfide isomerase PDIA3 to unfolded substrates. Binds protein substrates via a hydrophobic pocket in the C-terminal domain. May play a role in the unfolded stress response.
Subunit / interactions. Interacts with PDIA3.
Subcellular location. Endoplasmic reticulum lumen.
Induction. Induced by ER stress.
Similarity. Belongs to the protein disulfide isomerase family.
RefSeq proteins (2): NP_001287713, NP_689534* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR036249 | Thioredoxin-like_sf | Homologous_superfamily |
Pfam: PF13848
Enzyme classification (BRENDA):
- EC 5.3.4.1 — protein disulfide-isomerase (BRENDA: 81 organisms, 481 substrates, 347 inhibitors, 35 Km, 6 kcat entries)
Substrate kinetics (BRENDA)
15 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.
| Substrate | Km (mM) | Measurements |
|---|---|---|
| CYSTEINE | 1–3 | 3 |
| MYCOTHIOL-COUPLED HYDROXYETHYL DISULFIDE | 0.46–33.69 | 3 |
| RIBONUCLEASE | 0.002–0.01 | 3 |
| RNASE A | 0.007–0.05 | 3 |
| 2-MERCAPTOETHANOL | 0.2–0.8 | 2 |
| DITHIOTHREITOL | 0.003–0.0054 | 2 |
| GSH | 5–17 | 2 |
| RNASE | 0.028–0.063 | 2 |
| SCRAMBLED RIBONUCLEASE | 0.0011–0.0033 | 2 |
| DENATURED-REDUCED LYSOZYME | 0.0253 | 1 |
| INSULIN | 2.026 | 1 |
| INSULIN-(SS) | 0.005 | 1 |
| SCRAMBLED REOXIDIZED LYSOZYME | 0.0116 | 1 |
| SCRAMBLED RNASE | 0.02 | 1 |
| SRNASE | — | 0 |
UniProt features (36 total): helix 11, strand 9, mutagenesis site 6, turn 3, signal peptide 1, chain 1, domain 1, region of interest 1, short sequence motif 1, glycosylation site 1, sequence variant 1
Structure
Experimental structures (PDB)
2 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 4F9Z | X-RAY DIFFRACTION | 2.2 |
| 2L4C | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q96DN0-F1 | 86.76 | 0.79 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (1): 100
Mutagenesis-validated functional residues (6):
| Position | Phenotype |
|---|---|
| 231 | greatly reduces pdia3 binding in vivo and in vitro. |
| 232 | greatly reduces pdia3 binding in vivo and in vitro. |
| 233 | greatly reduces pdia3 binding in vivo and in vitro. |
| 168 | decreases somatostatin-14 binding. |
| 196 | decreases somatostatin-14 binding. |
| 196 | conserved pdia3 binding in vivo and in vitro. |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 97 (showing top):
GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GCANCTGNY_MYOD_Q6, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, CAGCTG_AP4_Q5, GOBP_PROTEIN_MATURATION, GOBP_PROTEIN_FOLDING, RICKMAN_HEAD_AND_NECK_CANCER_A, GOBP_RESPONSE_TO_TOPOLOGICALLY_INCORRECT_PROTEIN, GOCC_ENDOPLASMIC_RETICULUM_LUMEN, MARSON_BOUND_BY_FOXP3_STIMULATED, chr12p12, GOMF_INTRAMOLECULAR_OXIDOREDUCTASE_ACTIVITY, GOMF_ISOMERASE_ACTIVITY, FEVR_CTNNB1_TARGETS_UP, GOMF_PROTEIN_DISULFIDE_ISOMERASE_ACTIVITY
GO Biological Process (3): protein folding (GO:0006457), response to unfolded protein (GO:0006986), response to endoplasmic reticulum stress (GO:0034976)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (2): endoplasmic reticulum (GO:0005783), endoplasmic reticulum lumen (GO:0005788)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular process | 1 |
| protein maturation | 1 |
| response to topologically incorrect protein | 1 |
| cellular response to stress | 1 |
| binding | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| endoplasmic reticulum | 1 |
| intracellular organelle lumen | 1 |
Protein interactions and networks
STRING
1251 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ERP27 | PDIA3 | P30101 | 945 |
| ERP27 | CALR | P27797 | 703 |
| ERP27 | TXN | P10599 | 689 |
| ERP27 | ERP29 | P30040 | 605 |
| ERP27 | ERP44 | Q9BS26 | 569 |
| ERP27 | TMX3 | Q96JJ7 | 568 |
| ERP27 | PDIA5 | Q14554 | 558 |
| ERP27 | TXNDC12 | O95881 | 516 |
| ERP27 | TXNDC5 | Q8NBS9 | 513 |
| ERP27 | AGR3 | Q8TD06 | 496 |
| ERP27 | CLSTN3 | Q9BQT9 | 491 |
| ERP27 | TMX1 | Q9H3N1 | 486 |
| ERP27 | TMX4 | Q9H1E5 | 476 |
| ERP27 | CANX | P27824 | 468 |
| ERP27 | DNAJC10 | Q8IXB1 | 464 |
| ERP27 | AGR2 | O95994 | 464 |
IntAct
48 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| TAP1 | TAPBP | psi-mi:“MI:0914”(association) | 0.800 |
| ERP27 | SGTA | psi-mi:“MI:0915”(physical association) | 0.780 |
| SGTA | ERP27 | psi-mi:“MI:0915”(physical association) | 0.780 |
| EEF1D | ERP27 | psi-mi:“MI:0915”(physical association) | 0.740 |
| ERP27 | UBQLN1 | psi-mi:“MI:0915”(physical association) | 0.670 |
| UBQLN1 | ERP27 | psi-mi:“MI:0915”(physical association) | 0.670 |
| ERP27 | UBQLN1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| UBQLN1 | ERP27 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C12orf60 | ERP27 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GOLGA8F | ERP27 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ERP27 | UBQLN2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| UBL4A | ERP27 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ERP27 | MED20 | psi-mi:“MI:0915”(physical association) | 0.560 |
| BLOC1S2 | ERP27 | psi-mi:“MI:0915”(physical association) | 0.560 |
| HTT | ERP27 | psi-mi:“MI:0915”(physical association) | 0.560 |
| DDX11 | DNAJA2 | psi-mi:“MI:0914”(association) | 0.530 |
BioGRID (30): ERP27 (Two-hybrid), ERP27 (Two-hybrid), ERP27 (Two-hybrid), ERP27 (Two-hybrid), ERP27 (Two-hybrid), ERP27 (Two-hybrid), GOLGA8F (Two-hybrid), C12orf60 (Two-hybrid), UBQLN2 (Two-hybrid), BLOC1S2 (Two-hybrid), VARS (Affinity Capture-MS), EEF1A2 (Affinity Capture-MS), CARS (Affinity Capture-MS), EEF1D (Affinity Capture-MS), EEF1B2 (Affinity Capture-MS)
ESM2 similar proteins: A0A8M1N5Y4, A3KPF5, D7SFH9, O13811, O44342, P12865, P32474, P38658, P52588, Q0E0I1, Q0JD42, Q10057, Q17688, Q32L47, Q43116, Q498R3, Q4N4N8, Q53LQ0, Q54EN4, Q5FVM7, Q5R5L3, Q5RCM7, Q5WA72, Q5XI02, Q5ZKZ4, Q66GQ3, Q67IX6, Q69ST6, Q6AUC6, Q6NRT6, Q6P5E4, Q7XRB5, Q8IXB1, Q8N807, Q8VX13, Q8VZQ0, Q8W4J3, Q94F09, Q95LM0, Q96DN0
Diamond homologs: D3Z6P0, D4B2L8, G4NFB7, O13811, O22263, O48773, P00275, P04785, P05307, P07237, P08003, P09102, P09103, P0AA25, P0AA26, P0AA27, P0AA28, P0AA29, P0AA30, P11598, P13667, P17967, P21195, P27773, P29828, P30101, P34329, P38657, P38658, P38659, P38660, P38661, P52588, P52589, P54399, P55059, P75512, P80284, P97493, P97615
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
49 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 45 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1375 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 12:14915672:C:CT | acceptor_gain | 1.0000 |
| 12:14917322:T:C | acceptor_gain | 1.0000 |
| 12:14917325:CAG:C | acceptor_gain | 1.0000 |
| 12:14917326:A:T | acceptor_gain | 1.0000 |
| 12:14917327:G:GC | acceptor_gain | 1.0000 |
| 12:14917332:G:C | acceptor_gain | 1.0000 |
| 12:14917332:G:GC | acceptor_gain | 1.0000 |
| 12:14921045:CTAC:C | acceptor_gain | 1.0000 |
| 12:14933145:A:AC | donor_gain | 1.0000 |
| 12:14933146:C:CC | donor_gain | 1.0000 |
| 12:14934852:TTAC:T | donor_loss | 1.0000 |
| 12:14934853:TACCA:T | donor_loss | 1.0000 |
| 12:14934854:A:AC | donor_gain | 1.0000 |
| 12:14934855:C:CT | donor_gain | 1.0000 |
| 12:14934855:CCAGG:C | donor_gain | 1.0000 |
| 12:14934989:AAATC:A | acceptor_gain | 1.0000 |
| 12:14934992:TC:T | acceptor_gain | 1.0000 |
| 12:14934993:CC:C | acceptor_gain | 1.0000 |
| 12:14934994:C:CC | acceptor_gain | 1.0000 |
| 12:14934994:C:T | acceptor_gain | 1.0000 |
| 12:14937948:TAAC:T | donor_loss | 1.0000 |
| 12:14937949:AACCT:A | donor_loss | 1.0000 |
| 12:14938049:CCAT:C | acceptor_gain | 1.0000 |
| 12:14938050:CAT:C | acceptor_gain | 1.0000 |
| 12:14938050:CATC:C | acceptor_gain | 1.0000 |
| 12:14938051:AT:A | acceptor_gain | 1.0000 |
| 12:14938052:TCTAG:T | acceptor_loss | 1.0000 |
| 12:14938053:C:CC | acceptor_gain | 1.0000 |
| 12:14938053:CT:C | acceptor_loss | 1.0000 |
| 12:14914779:CTTT:C | acceptor_gain | 0.9900 |
AlphaMissense
1817 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 12:14915678:A:C | F195L | 0.976 |
| 12:14915678:A:T | F195L | 0.976 |
| 12:14915680:A:G | F195L | 0.976 |
| 12:14934919:G:C | S90R | 0.974 |
| 12:14934919:G:T | S90R | 0.974 |
| 12:14934921:T:G | S90R | 0.974 |
| 12:14917198:C:G | A186P | 0.964 |
| 12:14934860:C:G | R110P | 0.957 |
| 12:14915507:G:C | F252L | 0.956 |
| 12:14915507:G:T | F252L | 0.956 |
| 12:14915509:A:G | F252L | 0.956 |
| 12:14917197:G:T | A186D | 0.953 |
| 12:14917263:A:G | L164P | 0.952 |
| 12:14917210:A:C | Y182D | 0.946 |
| 12:14915596:C:G | A223P | 0.944 |
| 12:14920977:G:C | F135L | 0.943 |
| 12:14920977:G:T | F135L | 0.943 |
| 12:14920979:A:G | F135L | 0.943 |
| 12:14937962:C:T | G62D | 0.938 |
| 12:14915519:A:C | F248L | 0.936 |
| 12:14915519:A:T | F248L | 0.936 |
| 12:14915521:A:G | F248L | 0.936 |
| 12:14915590:A:C | Y225D | 0.935 |
| 12:14937958:G:C | F63L | 0.929 |
| 12:14937958:G:T | F63L | 0.929 |
| 12:14937960:A:G | F63L | 0.929 |
| 12:14937968:A:T | V60D | 0.928 |
| 12:14934861:G:T | R110S | 0.927 |
| 12:14915627:G:C | F212L | 0.925 |
| 12:14915627:G:T | F212L | 0.925 |
dbSNP variants (sampled 300 via entrez): RS1000374341 (12:14926023 T>C), RS1000414203 (12:14931818 G>A,C), RS1000434611 (12:14936917 G>A,T), RS1000508491 (12:14940469 A>G), RS1000686643 (12:14935644 C>T), RS1000717024 (12:14935910 T>C,G), RS1000801089 (12:14921112 T>C), RS1000807224 (12:14936718 C>A,G,T), RS1000808452 (12:14920821 T>C), RS1001062613 (12:14925991 C>A), RS1001195227 (12:14919830 T>C,G), RS1001219164 (12:14913786 T>C,G), RS1001232833 (12:14935967 C>T), RS1001248895 (12:14914016 C>G), RS1001301205 (12:14930717 T>C)
Disease associations
OMIM: gene MIM:610642 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
5 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST005235_5 | Hand grip strength | 2.000000e-12 |
| GCST009596_4 | Osteoarthritis of the hand | 2.000000e-15 |
| GCST90007527_4 | Low hand grip strength (60 years and older) (EWGSOP) | 4.000000e-09 |
| GCST90010716_1 | Hand osteoarthritis severity (hand Klsum) | 3.000000e-12 |
| GCST90010717_1 | Finger osteoarthritis severity (hand Klsum) | 5.000000e-14 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0006941 | grip strength measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
60 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | increases expression, decreases expression, affects cotreatment | 6 |
| Benzo(a)pyrene | affects methylation, decreases expression, increases methylation | 5 |
| trichostatin A | affects cotreatment, increases expression | 3 |
| sodium arsenite | decreases expression | 3 |
| Cyclosporine | decreases expression | 3 |
| bisphenol A | affects expression | 2 |
| mercuric bromide | affects cotreatment, increases expression | 2 |
| perfluoro-n-nonanoic acid | decreases expression | 2 |
| entinostat | decreases expression, affects cotreatment | 2 |
| Vorinostat | affects cotreatment, increases expression | 2 |
| Panobinostat | affects cotreatment, increases expression | 2 |
| Estradiol | affects cotreatment, increases expression, decreases expression | 2 |
| Ethinyl Estradiol | affects expression, decreases expression | 2 |
| Phenylmercuric Acetate | affects cotreatment, increases expression | 2 |
| Tetrachlorodibenzodioxin | decreases expression | 2 |
| Tobacco Smoke Pollution | decreases expression | 2 |
| Tretinoin | increases expression | 2 |
| Aflatoxin B1 | affects expression, increases methylation | 2 |
| Cadmium Chloride | decreases expression, increases abundance | 2 |
| p-Chloromercuribenzoic Acid | affects cotreatment, increases expression | 2 |
| dicrotophos | decreases expression | 1 |
| methyleugenol | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| propionaldehyde | decreases expression | 1 |
| terbufos | increases methylation | 1 |
| 3,4-dichloroaniline | decreases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| perfluorooctanoic acid | decreases expression | 1 |
| 1-hydroxypyrene | decreases expression | 1 |
| pentanal | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): osteoarthritis, hand